Took the chart back out to March of last year to do a little fib retracement. Wouldn't you know, NASDAQ:CLVS has been channel bound for a minute between the 618 and 786 fib lines with pretty clear support and resistance levels at each. Since it retraced back to the 786 again and is holding (for now), volume is likely going to be the "friend" or "foe" depending on how you're looking to trade this stock. You've also got the 50DMA to keep track of, which has also been a decent level of resistance over the past week or so.
Fundamentally, I'm looking to see if speculation starts building later down the line after they announced that they initiated sponsored clinical development of FAP-2286 with the Phase 1/2 LuMIERE clinical trial in patients with FAP-positive solid tumors which is now enrolling. Either way, cancer stocks seem to be picking up some steam. Whether it's targeted treatments or drug delivery technology, oncology is beginning to take its own slice of biotech lately.
Fundamentally, I'm looking to see if speculation starts building later down the line after they announced that they initiated sponsored clinical development of FAP-2286 with the Phase 1/2 LuMIERE clinical trial in patients with FAP-positive solid tumors which is now enrolling. Either way, cancer stocks seem to be picking up some steam. Whether it's targeted treatments or drug delivery technology, oncology is beginning to take its own slice of biotech lately.